503 related articles for article (PubMed ID: 27109816)
21. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
[TBL] [Abstract][Full Text] [Related]
22. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
Pohunek P; Varoli G; Reznichenko Y; Mokia-Serbina S; Brzostek J; Kostromina V; Kaladze M; Muraro A; Carzana E; Armani S; Kaczmarek J
Eur J Pediatr; 2021 May; 180(5):1467-1475. PubMed ID: 33404895
[TBL] [Abstract][Full Text] [Related]
23. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
[TBL] [Abstract][Full Text] [Related]
24. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.
Quinn D; Seale JP; Reisner C; Fischer T; Golden M; Fernandez C; Darken P; St Rose E; Thomas M; Tardie G; Orevillo C
Respir Med; 2014 Sep; 108(9):1327-35. PubMed ID: 25060541
[TBL] [Abstract][Full Text] [Related]
25. Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).
Beeh KM; Emirova A; Prunier H; Santoro D; Nandeuil MA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1701-1711. PubMed ID: 29872288
[TBL] [Abstract][Full Text] [Related]
26. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
27. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
[TBL] [Abstract][Full Text] [Related]
28. The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Skloot GS; Guasconi A; Lavon BR; Georges G; De Backer W; Galkin D; Cortellini M; Panni I; Bates JHT
Respir Res; 2023 Oct; 24(1):244. PubMed ID: 37803368
[TBL] [Abstract][Full Text] [Related]
29. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
[TBL] [Abstract][Full Text] [Related]
31. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.
Rogliani P; Ora J; Girolami A; Rossi I; de Guido I; Facciolo F; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2021 Aug; 69():102050. PubMed ID: 34129945
[TBL] [Abstract][Full Text] [Related]
32. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
[TBL] [Abstract][Full Text] [Related]
35. Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.
Singh D
Expert Opin Pharmacother; 2018 Aug; 19(11):1279-1287. PubMed ID: 29985096
[TBL] [Abstract][Full Text] [Related]
36. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
[TBL] [Abstract][Full Text] [Related]
37. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
38. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Vos W; Verlinden I; Van Holsbeke C; Clukers J; Hajian B; Siddiqui S; Jenkins M; Reisner C; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():2673-2684. PubMed ID: 30214185
[TBL] [Abstract][Full Text] [Related]
39. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
40. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
